Abstract
Hypokalaemia (defined as a plasma potassium concentration < 3.5 mEq/L) is a common electrolyte abnormality in clinical practice. Drugs are a common cause of either asymptomatic or symptomatic hypokalaemia. Drug-induced hypokalaemia is an important problem particularly in the elderly and in patients with cardiovascular, renal or hepatic disease. Hypokalaemia can complicate the use of the drug in the therapeutic concentration range, and can also be precipitated with overdose or conditions leading to drug intoxication. Because the etiologies of hypokalaemia are numerous, the diagnosis of drug-induced hypokalaemia may be overlooked. Physicians should always pay close attention to this common side effect. Evaluation and management of a hypokalaemic patient should include a careful review of medications history to determine if a drug capable of causing or aggravating this electrolyte abnormality is present.
Current Drug Safety
Title: Drug-Induced Hypokalaemia
Volume: 4 Issue: 1
Author(s): Chaker Ben Salem, Houssem Hmouda and Kamel Bouraoui
Affiliation:
Abstract: Hypokalaemia (defined as a plasma potassium concentration < 3.5 mEq/L) is a common electrolyte abnormality in clinical practice. Drugs are a common cause of either asymptomatic or symptomatic hypokalaemia. Drug-induced hypokalaemia is an important problem particularly in the elderly and in patients with cardiovascular, renal or hepatic disease. Hypokalaemia can complicate the use of the drug in the therapeutic concentration range, and can also be precipitated with overdose or conditions leading to drug intoxication. Because the etiologies of hypokalaemia are numerous, the diagnosis of drug-induced hypokalaemia may be overlooked. Physicians should always pay close attention to this common side effect. Evaluation and management of a hypokalaemic patient should include a careful review of medications history to determine if a drug capable of causing or aggravating this electrolyte abnormality is present.
Export Options
About this article
Cite this article as:
Salem Ben Chaker, Hmouda Houssem and Bouraoui Kamel, Drug-Induced Hypokalaemia, Current Drug Safety 2009; 4 (1) . https://dx.doi.org/10.2174/157488609787354369
DOI https://dx.doi.org/10.2174/157488609787354369 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Atorvastatin Therapy Lowers Circulating Cholesterol but not Free Radical Activity in Advance of Identifiable Clinical Benefit in the Treatment of Mild-to-Moderate AD
Current Alzheimer Research Identification and Quantitation of Some Characteristic Phenolic Compounds in Elderberry Juice by HPLC with Coulometric Electrode Array Detection
Current Bioactive Compounds A Multidisciplinary Atrial Fibrillation Clinic
Current Cardiology Reviews Structural Characterization, Biological Effects, and Synthetic Studies on Xanthones from Mangosteen (Garcinia mangostana), a Popular Botanical Dietary Supplement
Mini-Reviews in Organic Chemistry Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Will Sodium Intake Reduction Improve Cardiovascular Outcomes in the General Population? A Critical Review of Current Evidence
Current Hypertension Reviews Obesity-Associated Hypertension in Childhood: A New Epidemic Problem
Current Hypertension Reviews Advances in the Chemistry of Saccharins: From Synthetic Novelties Towards Biologically Active Compounds
Current Medicinal Chemistry Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design PUFA for Human Health: Diet or Supplementation?
Current Pharmaceutical Design Molecular Imaging to Monitor Repair of Myocardial Infarction Using Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells
Current Gene Therapy Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Current Bioactive Compounds Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry High Blood Pressure and the Risk of Stroke
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy